Dazodalibep Shows Phase 3 Benefit in Sjögren Disease
Amgen's dazodalibep showed significant reduction in systemic disease activity in Sjögren's patients in a phase 3 trial, with both dosing regimens outperforming placebo. The every-4-weeks regimen also improved patient-reported dryness. Common side effects were mild to moderate. Amgen is conducting further trials. According to the company, results support dazodalibep's potential as a first-in-class treatment.
How this was made

The 30-second read
Why it matters
The data could position Amgen as a leader in this niche, prompting analyst upgrades.
Market read
First‑in‑class Phase 3 success may drive Amgen stock higher and influence the autoimmune biotech sector.
What to watch
Regulatory pathway timing and reimbursement landscape could temper upside.
Background
Sjögren disease lacks approved disease‑modifying therapies; Amgen's dazodalibep is a novel CD40L antagonist.
Ticker impact
Amgen announced positive Phase 3 results for its CD40L antagonist dazodalibep in Sjögren disease, showing significant reduction in disease activity.
likely upward pressure as investors price in a first‑in‑class therapy for an unmet autoimmune market
Phase 3 efficacy and safety data are new, material, and could drive near‑term buying interest.
Market effects
May boost the broader autoimmune‑therapy sector and increase interest in CD40L‑targeted drugs.
U.S. biotech stocks could see modest gains.
Potentially relevant for global investors tracking rare‑disease pipelines.
Counterpoint
Skeptics may question long‑term safety or market uptake given competition in autoimmune space.
Key entities
- CompanyAmgen
Developer of dazodalibep
- DrugDazodalibep
Investigational CD40L antagonist



